Trial Profile
A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Cytarabine; Etoposide
- Indications Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Proof of concept
- Acronyms POETIC
- 05 Sep 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2017 Results published in the Pediatric Blood and Cancer
- 17 Oct 2016 Planned End Date changed from 1 Jul 2014 to 1 Jul 2017.